Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks?

The FDA accepted DemeRx’s IND for oral noribogaine (DMX-1001) in April 2026, advancing a longer-acting metabolite of ibogaine as a potential treatment for alcohol use disorder (AUD) through neuroplasticity and polypharmacology. We explore the science, preclinical data, early Phase 1 results, related ibogaine/noribogaine studies, and what this could mean for the millions struggling with AUD. Tune in for a balanced look at the pros, cons, limitations, and practical implications of this emerging therapy.20